Drug Trial Radar · NCT00790933
An Open-label Study of Vedolizumab (MLN0002) in Participants With Ulcerative Colitis and Crohn's Disease
Last checked: Nov 20, 2026Latest source record: May 24, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
2,243
Actual
Start
May 22, 2009
Primary completion
Oct 31, 2017
Study completion Oct 31, 2017
Sponsor
- Lead sponsor
- TakedaTakeda (TAK)
- Sponsor type
- Industry
- First posted
- Nov 14, 2008
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Other
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this multicenter, open-label study is to collect data on the occurrence of important clinical safety events resulting from chronic vedolizumab (MLN0002) administration.
Conditions
- Ulcerative Colitis
- Crohn's Disease
Interventions
VedolizumabDrug
Vedolizumab intravenous infusion
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants With One or More Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)Time frame: From first dose of study drug in this study through 16 weeks after the last dose of study drug (Up to approximately 8.5 years)
- Number of Participants With Markedly Abnormal Safety Laboratory FindingsTime frame: From first dose of study drug in this study through 16 weeks after the last dose of study drug (Up to 8.5 years)
- Percentage of Participants With at Least One Clinically Significant Mean Change Over Time in Vital Sign MeasurementsTime frame: From first dose of study drug in this study through 16 weeks after the last dose of study drug (Up to 8.5 years)
- Number of Participants With at Least One Clinically Significant Electrocardiogram (ECG) FindingsTime frame: From first dose of study drug in this study through 16 weeks after the last dose of study drug (Up to 8.5 years)
- Time to Major Inflammatory Bowel Disease (IBD) - Related EventsTime frame: Baseline (Prior to first dose of study drug in C13008) up to end of study (approximately up to 8.5 years)
- Change From Baseline in the Inflammatory Bowel Disease Questionnaire (IBDQ) Scores at Week 28Time frame: Baseline (prior to first dose of study drug in C13008; for rollover participants this was the last assessment from the previous study) and Week 28
- Change From Baseline in the Inflammatory Bowel Disease Questionnaire (IBDQ) Scores at Week 52Time frame: Baseline (prior to first dose of study drug in C13008; for rollover participants this was the last assessment from the previous study) and Week 52
- Change From Baseline in the Inflammatory Bowel Disease Questionnaire (IBDQ) Scores at Week 76Time frame: Baseline (prior to first dose of study drug in C13008; for rollover participants this was the last assessment from the previous study) and Week 76
- Change From Baseline in the Inflammatory Bowel Disease Questionnaire (IBDQ) Scores at Week 100Time frame: Baseline (prior to first dose of study drug in C13008; for rollover participants this was the last assessment from the previous study) and Week 100
- Change From Baseline in the Inflammatory Bowel Disease Questionnaire (IBDQ) Scores at Week 124Time frame: Baseline (prior to first dose of study drug in C13008; for rollover participants this was the last assessment from the previous study) and Week 124
- Change From Baseline in the Inflammatory Bowel Disease Questionnaire (IBDQ) Scores at Week 148Time frame: Baseline (prior to first dose of study drug in C13008; for rollover participants this was the last assessment from the previous study) and Week 148
- Change From Baseline in the Inflammatory Bowel Disease Questionnaire (IBDQ) Scores at Week 172Time frame: Baseline (prior to first dose of study drug in C13008; for rollover participants this was the last assessment from the previous study) and Week 172
- Change From Baseline in the Inflammatory Bowel Disease Questionnaire (IBDQ) Scores at Week 196Time frame: Baseline (prior to first dose of study drug in C13008; for rollover participants this was the last assessment from the previous study) and Week 196
- Change From Baseline in the Inflammatory Bowel Disease Questionnaire (IBDQ) Scores at Week 248Time frame: Baseline (prior to first dose of study drug in C13008; for rollover participants this was the last assessment from the previous study) and Week 248
- Change From Baseline in the Inflammatory Bowel Disease Questionnaire (IBDQ) Scores at Week 300Time frame: Baseline (prior to first dose of study drug in C13008; for rollover participants this was the last assessment from the previous study) and Week 300
- Change From Baseline in the Inflammatory Bowel Disease Questionnaire (IBDQ) Scores at Week 352Time frame: Baseline (prior to first dose of study drug in C13008; for rollover participants this was the last assessment from the previous study) and Week 352
- Change From Baseline in Short Form-36 (SF-36) Physical Component Scores at Week 28Time frame: Baseline (prior to first dose of study drug in C13008; for rollover participants this was the last assessment from the previous study) and Week 28
- Change From Baseline in Short Form-36 (SF-36) Mental Component Scores at Week 28Time frame: Baseline (prior to first dose of study drug in C13008; for rollover participants this was the last assessment from the previous study) and Week 28
- Change From Baseline in Short Form-36 (SF-36) Physical Component Score at Week 52Time frame: Baseline (prior to first dose of study drug in C13008; for rollover participants this was the last assessment from the previous study) and Week 52
- Change From Baseline in Short Form-36 (SF-36) Mental Component Score at Week 52Time frame: Baseline (prior to first dose of study drug in C13008; for rollover participants this was the last assessment from the previous study) and Week 52
- Change From Baseline in Short Form-36 (SF-36) Physical Component at Week 76Time frame: Baseline (prior to first dose of study drug in C13008; for rollover participants this was the last assessment from the previous study) and Week 76
- Change From Baseline in Short Form-36 (SF-36) Mental Component Score at Week 76Time frame: Baseline (prior to first dose of study drug in C13008; for rollover participants this was the last assessment from the previous study) and Week 76
- Change From Baseline in Short Form-36 (SF-36) Physical Component Score at Week 100Time frame: Baseline (prior to first dose of study drug in C13008; for rollover participants this was the last assessment from the previous study) and Week 100
- Change From Baseline in Short Form-36 (SF-36) Mental Component Score at Week 100Time frame: Baseline (prior to first dose of study drug in C13008; for rollover participants this was the last assessment from the previous study) and Week 100
- Change From Baseline in Short Form-36 (SF-36) Physical Component Scores at Week 124Time frame: Baseline (prior to first dose of study drug in C13008; for rollover participants this was the last assessment from the previous study) and Week 124
- Change From Baseline in Short Form-36 (SF-36) Mental Component Scores at Week 124Time frame: Baseline (prior to first dose of study drug in C13008; for rollover participants this was the last assessment from the previous study) and Week 124
- Change From Baseline in Short Form-36 (SF-36) Physical Component Score at Week 148Time frame: Baseline (prior to first dose of study drug in C13008; for rollover participants this was the last assessment from the previous study) and Week 148
- Change From Baseline in Short Form-36 (SF-36) Mental Component Score at Week 148Time frame: Baseline (prior to first dose of study drug in C13008; for rollover participants this was the last assessment from the previous study) and Week 148
- Change From Baseline in Short Form-36 (SF-36) Physical Component Scores at Week 172Time frame: Baseline (prior to first dose of study drug in C13008; for rollover participants this was the last assessment from the previous study) and Week 172
- Change From Baseline in Short Form-36 (SF-36) Mental Component Scores at Week 172Time frame: Baseline (prior to first dose of study drug in C13008; for rollover participants this was the last assessment from the previous study) and Week 172
- Change From Baseline in Short Form-36 (SF-36) Physical Component Score at Week 196Time frame: Baseline (prior to first dose of study drug in C13008; for rollover participants this was the last assessment from the previous study) and Week 196
- Change From Baseline in Short Form-36 (SF-36) Mental Component Score at Week 196Time frame: Baseline (prior to first dose of study drug in C13008; for rollover participants this was the last assessment from the previous study) and Week 196
- Change From Baseline in Short Form-36 (SF-36) Physical Component Score at Week 248Time frame: Baseline (prior to first dose of study drug in C13008; for rollover participants this was the last assessment from the previous study) and Week 248
- Change From Baseline in Short Form-36 (SF-36) Mental Component Score at Week 248Time frame: Baseline (prior to first dose of study drug in C13008; for rollover participants this was the last assessment from the previous study) and Week 248
- Change From Baseline in Short Form-36 (SF-36) Physical Component Score at Week 300Time frame: Baseline (prior to first dose of study drug in C13008; for rollover participants this was the last assessment from the previous study) and Week 300
- Change From Baseline in Short Form-36 (SF-36) Mental Component Score at Week 300Time frame: Baseline (prior to first dose of study drug in C13008; for rollover participants this was the last assessment from the previous study) and Week 300
- Change From Baseline in Short Form-36 (SF-36) Physical Component Score at Week 352Time frame: Baseline (prior to first dose of study drug in C13008; for rollover participants this was the last assessment from the previous study) and Week 352
- Change From Baseline in Short Form-36 (SF-36) Mental Component Score at Week 352Time frame: Baseline (prior to first dose of study drug in C13008; for rollover participants this was the last assessment from the previous study) and Week 352
- Change From Baseline in European Quality of Life 5-Dimension (EQ-5D) Health States Composite Score at Week 28Time frame: Baseline (prior to first dose of study drug in C13008; for rollover participants this was the last assessment from the previous study) and Week 28
- Change From Baseline in European Quality of Life 5-Dimension (EQ-5D) Health States Visual Analog Scale (VAS) Score at Week 28Time frame: Baseline (prior to first dose of study drug in C13008; for rollover participants this was the last assessment from the previous study) and Week 28
- Change From Baseline in European Quality of Life 5-Dimension (EQ-5D) Health States Composite Score at Week 52Time frame: Baseline (prior to first dose of study drug in C13008; for rollover participants this was the last assessment from the previous study) and Week 52
- Change From Baseline in European Quality of Life 5-Dimension (EQ-5D) Health States Visual Analog Scale (VAS) Score at Week 52Time frame: Baseline (prior to first dose of study drug in C13008; for rollover participants this was the last assessment from the previous study) and Week 52
- Change From Baseline in European Quality of Life 5-Dimension (EQ-5D) Health States Composite Score at Week 76Time frame: Baseline (prior to first dose of study drug in C13008; for rollover participants this was the last assessment from the previous study) and Week 76
- Change From Baseline in European Quality of Life 5-Dimension (EQ-5D) Health States Visual Analog Scale (VAS) Score at Week 76Time frame: Baseline (prior to first dose of study drug in C13008; for rollover participants this was the last assessment from the previous study) and Week 76
- Change From Baseline in European Quality of Life 5-Dimension (EQ-5D) Health States Composite Score at Week 100Time frame: Baseline (prior to first dose of study drug in C13008; for rollover participants this was the last assessment from the previous study) and Week 100
- Change From Baseline in European Quality of Life 5-Dimension (EQ-5D) Health States Visual Analog Scale (VAS) Score at Week 100Time frame: Baseline (prior to first dose of study drug in C13008; for rollover participants this was the last assessment from the previous study) and Week 100
- Change From Baseline in European Quality of Life 5-Dimension (EQ-5D) Health States Composite Score at Week 124Time frame: Baseline (prior to first dose of study drug in C13008; for rollover participants this was the last assessment from the previous study) and Week 124
- Change From Baseline in European Quality of Life 5-Dimension (EQ-5D) Health States Visual Analog Scale (VAS) Score at Week 124Time frame: Baseline (prior to first dose of study drug in C13008; for rollover participants this was the last assessment from the previous study) and Week 124
- Change From Baseline in European Quality of Life 5-Dimension (EQ-5D) Health States Composite Score at Week 148Time frame: Baseline (prior to first dose of study drug in C13008; for rollover participants this was the last assessment from the previous study) and Week 148
- Change From Baseline in European Quality of Life 5-Dimension (EQ-5D) Health States Visual Analog Scale (VAS) Score at Week 148Time frame: Baseline (prior to first dose of study drug in C13008; for rollover participants this was the last assessment from the previous study) and Week 148
- Change From Baseline in European Quality of Life 5-Dimension (EQ-5D) Health States Composite Score at Week 172Time frame: Baseline (prior to first dose of study drug in C13008; for rollover participants this was the last assessment from the previous study) and Week 172
- Change From Baseline in European Quality of Life 5-Dimension (EQ-5D) Health States Visual Analog Scale (VAS) Score at Week 172Time frame: Baseline (prior to first dose of study drug in C13008; for rollover participants this was the last assessment from the previous study) and Week 172
- Change From Baseline in European Quality of Life 5-Dimension (EQ-5D) Health States Composite Score at Week 196Time frame: Baseline (prior to first dose of study drug in C13008; for rollover participants this was the last assessment from the previous study) and Week 196
- Change From Baseline in European Quality of Life 5-Dimension (EQ-5D) Health States Visual Analog Scale (VAS) Score at Week 196Time frame: Baseline (prior to first dose of study drug in C13008; for rollover participants this was the last assessment from the previous study) and Week 196
- Change From Baseline in European Quality of Life 5-Dimension (EQ-5D) Health States Composite Score at Week 248Time frame: Baseline (prior to first dose of study drug in C13008; for rollover participants this was the last assessment from the previous study) and Week 248
- Change From Baseline in European Quality of Life 5-Dimension (EQ-5D) Health States Visual Analog Scale (VAS) Score at Week 248Time frame: Baseline (prior to first dose of study drug in C13008; for rollover participants this was the last assessment from the previous study) and Week 248
- Change From Baseline in European Quality of Life 5-Dimension (EQ-5D) Health States Composite Score at Week 300Time frame: Baseline (prior to first dose of study drug in C13008; for rollover participants this was the last assessment from the previous study) and Week 300
- Change From Baseline in EuroQol 5D Health States (EQ-5D) Visual Analog Scale (VAS) Score at Week 300Time frame: Baseline (prior to first dose of study drug in C13008; for rollover participants this was the last assessment from the previous study) and Week 300
- Change From Baseline in European Quality of Life 5-Dimension (EQ-5D) Health States Composite Score at Week 352Time frame: Baseline (prior to first dose of study drug in C13008; for rollover participants this was the last assessment from the previous study) and Week 352
- Change From Baseline in European Quality of Life 5-Dimension (EQ-5D) Health States Visual Analog Scale (VAS) Score at Week 352Time frame: Baseline (prior to first dose of study drug in C13008; for rollover participants this was the last assessment from the previous study) and Week 352
Locations
41 sites in 10 countries. Site status is shown where the registry gives one.
Site not named
Birmingham, Alabama
Site not named
San Diego, California
Site not named
San Francisco, California
Site not named
Lafayette, Colorado
Site not named
Littleton, Colorado
Site not named
Thornton, Colorado
Site not named
Hamden, Connecticut
Site not named
Jacksonville, Florida
Site not named
Miami, Florida
Site not named
Winter Park, Florida
Site not named
Atlanta, Georgia
Site not named
Decatur, Georgia
Site not named
Macon, Georgia
Site not named
Topeka, Kansas
Site not named
Louisville, Kentucky
Site not named
Baton Rouge, Louisiana
Site not named
Chevy Chase, Maryland
Site not named
Ann Arbor, Michigan
Site not named
Troy, Michigan
Site not named
Rochester, Minnesota
Site not named
Cheektowaga, New York
Site not named
New York, New York
Site not named
Charlotte, North Carolina
Site not named
Elkin, North Carolina
Site not named
Portland, Oregon
Site not named
Germantown, Tennessee
Site not named
San Antonio, Texas
Site not named
Tyler, Texas
Site not named
Charlottesville, Virginia
Site not named
Richmond, Virginia
Site not named
Milwaukee, Wisconsin
Site not named
Adelaide, South Australia, Australia
Site not named
Leuven, Belgium
Site not named
Edmonton, Alberta, Canada
Site not named
Saskatoon, Saskatchewan, Canada
Site not named
Prague, Czechia
Site not named
Halle, Saint, Germany
Site not named
Szekszárd, Hungary
Site not named
Tel Aviv, Israel
Site not named
Kuala Lumpur, Malaysia
Showing 40 of 41 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.